Epidermal Nevus Syndrome Clinical Trials 2026 — Find Recruiting Studies

About Epidermal Nevus Syndrome

Epidermal nevus syndrome encompasses a heterogeneous group of neurocutaneous disorders characterised by the presence of epidermal nevi in association with systemic abnormalities affecting the brain, eyes, and skeleton, all arising from somatic (post-zygotic) mutations in genes regulating cell growth, including FGFR3, PIK3CA, and HRAS. Because the mutations arise post-fertilisation, they are present only in a mosaic distribution following Blaschko's lines, and are not detectable in blood in a significant proportion of cases — requiring skin biopsy from affected tissue for molecular diagnosis. The syndrome spectrum includes Schimmelpenning syndrome (sebaceous nevus), pigmented epidermal nevus syndrome, and keratinocytic epidermal nevus syndrome.

Common Clinical Features

Linear, verrucous, or sebaceous epidermal nevi distributed along Blaschko's lines, present from birth Neurological abnormalities: epilepsy (often refractory), intellectual disability, and hemimegalencephaly Ocular abnormalities: coloboma, corneal opacification, and lipodermoid lesions of the conjunctiva Skeletal anomalies: hemihypertrophy, vitamin D-resistant rickets (hypophosphataemic rickets), and scoliosis Risk of malignant transformation of sebaceous nevi (basal cell carcinoma, sebaceous carcinoma) in adult life Cardiovascular abnormalities in some subtypes including ventricular septal defects Renal anomalies including renal cysts and Wilms tumour predisposition in PIK3CA-related subtypes

Clinical Trial Eligibility Tips

What to know before applying to Epidermal Nevus Syndrome trials.

Blood-based genetic testing is frequently negative due to somatic mosaicism — trials targeting PIK3CA or FGFR3 pathway require skin biopsy from affected nevus tissue with next-generation sequencing at adequate variant allele frequency.

PIK3CA-related overgrowth spectrum (PROS) trials may include ENS patients with PIK3CA mutations — confirm eligibility under PROS umbrella protocols which may have broader inclusion criteria.

Multidisciplinary baseline assessment including neurology (MRI brain), ophthalmology, and skeletal survey is typically required; compile all recent specialist reports before approaching trial sites.